PHCU.F Stock Overview
Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Photocure ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 4.48 |
| 52 Week High | NOK 6.50 |
| 52 Week Low | NOK 4.47 |
| Beta | 0.99 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -59.71% |
| Change since IPO | -52.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHCU.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 0.5% |
| 1Y | n/a | 13.1% | 30.7% |
Return vs Industry: Insufficient data to determine how PHCU.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PHCU.F performed against the US Market.
Price Volatility
| PHCU.F volatility | |
|---|---|
| PHCU.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHCU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PHCU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 102 | Dan Schneider | www.photocure.com |
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
Photocure ASA Fundamentals Summary
| PHCU.F fundamental statistics | |
|---|---|
| Market cap | US$120.74m |
| Earnings (TTM) | US$1.28m |
| Revenue (TTM) | US$47.55m |
94.2x
P/E Ratio2.5x
P/S RatioIs PHCU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHCU.F income statement (TTM) | |
|---|---|
| Revenue | NOK 526.25m |
| Cost of Revenue | NOK 29.11m |
| Gross Profit | NOK 497.15m |
| Other Expenses | NOK 482.98m |
| Earnings | NOK 14.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.52 |
| Gross Margin | 94.47% |
| Net Profit Margin | 2.69% |
| Debt/Equity Ratio | 0% |
How did PHCU.F perform over the long term?
See historical performance and comparison